IP Library Granted Patent US 10,046,011
Granted Patent B2
US 10,046,011 · App. 14/652,324 · Granted Aug 14, 2018

Compositions for inducing or suppressing an immune response

Inventors: Yufang Shi (Belle Mead, NJ); Guangwen Ren (Piscataway, NJ); Liying Zhang (Belle Mead, NJ)
Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
A61K35/28A61K38/191A61K38/2006A61K38/217A61K45/06C12N5/0663A61K2035/122C12N2500/05C12N2501/10C12N2501/2301C12N2501/2317C12N2501/24C12N2501/25C12N2502/1114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,011
App. No.
14/652,324
Granted
Aug 14, 2018
Kind
B2
Abstract

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Claims (8)

1. A composition comprising

(a) a population of isolated mesenchymal stem cells produced by a method comprising the steps of :

(i) obtaining multipotent progenitor cells;

(ii) culturing said multipotent cells in a medium to produce a subpopulation of mesenchymal stem cells and a subpopulation of differentiated cells;

(iii) separating mesenchymal stem cells from differentiated cells in said medium;

(iv) treating the mesenchymal cells with functional Type 1 interferon α (IFN-I α) or transducing the mesenchymal stem cells to release functional IFN-I α; and

(v) activating at least a subset of said separated mesenchymal stem cells with interferon gamma (IFNγ) and at least one cytokine selected from the group consisting of interleukin-1 alpha (IL-1 α), interleukin-1 beta (IL-1 (β), tumor necrosis factor alpha (TNF α), Type 1 interferons (IFN-I), transforming growth factor β(TGFβ), and fibroblast growth factor (FGF) for a sufficient period of time such that the activated mesenchymal stem cells are immunomodulatory.

2. The composition of claim 1 , wherein the activated immunomodulatory mesenchymal stem cells are immune stimulatory.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2015
From: SHI, YUFANG; REN, GUANGWEN; ZHANG, LIYING
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 035910/0235 →
Continuity (4)
Continuation In Part 12362847 · Jan 30, 2009
Provisional Application 61737616 · Dec 14, 2012
Provisional Application 61063288 · Jan 31, 2008
Related Publication 20150313946A1 · Nov 5, 2015
Cited By (2)
US 12,209,255 US 12,465,621